MedTrace Logo

Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer

NCT04736173 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 169

Last updated 2026-05-01

No results posted yet for this study

Summary

This is a phase 2 study to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) in front-line, PD-L1-high, locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC).

Conditions

  • Non Small Cell Lung Cancer
  • Nonsquamous Non Small Cell Lung Cancer
  • Squamous Non Small Cell Lung Cancer
  • Lung Cancer

Interventions

DRUG

Domvanalimab

Domvanalimab is a humanized monoclonal antibody targeting human TIGIT

DRUG

Zimberelimab

Zimberelimab is a fully human anti-PD-1 monoclonal antibody

DRUG

Carboplatin

Participants receive carboplatin, pemetrexed, and paclitaxel at a target area under the curve.

DRUG

Paclitaxel

Participants receive carboplatin, pemetrexed, and paclitaxel at a target area under the curve.

DRUG

Pemetrexed

Participants receive carboplatin, pemetrexed, and paclitaxel at a target area under the curve.

DRUG

Pembrolizumab

Pembrolizumab is a humanized Immunoglobulin G4 monoclonal antibody targeting the PD-1 receptor

Sponsors & Collaborators

  • Gilead Sciences

    collaborator INDUSTRY

  • Arcus Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Medical Director · Arcus Biosciences, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-08
Primary Completion
2027-05-31
Completion
2027-05-31
FDA Drug
Yes

Countries

  • United States
  • Hong Kong
  • Malaysia
  • Philippines
  • South Africa
  • South Korea
  • Taiwan
  • Thailand
  • Turkey (Türkiye)
  • Vietnam

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04736173 on ClinicalTrials.gov